The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
A Combined Analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council Randomized Clinical Trials for the Prophylactic Treatment of Stage TaT1 Bladder Cancer
Abstract
PURPOSE: The use of prophylactic agents after primary resection can decrease the incidence of tumor recurrence in patients with stage TaT1 bladder cancer. However, the long-term impact on progression to muscle invasive disease as well as on duration of survival is unknown. A combined analysis of individual patient data from previously performed European Organization for Research and Treatment of Cancer (EORTC) and Medical Research Council (MRC) randomized clinical trials was done in an attempt to answer these crucial questions. We compared immediate versus no adjuvant prophylactic treatment after transurethral resection with respect to disease-free interval, time to progression to muscle invasive disease, time to appearance of distant metastases, duration of survival and progression-free survival. MATERIALS AND METHODS: All EORTC and MRC prophylactic, randomized phase III trials with primary or recurrent, stage TaT1 transitional cell bladder cancer that compared transurethral resection alone or with adjuvant prophylactic treatment were included in the study. Four EORTC and 2 MRC trials using intravesical chemotherapy or oral agents and including a total of 2,535 patients were studied. RESULTS: A statistically significant effect of adjuvant treatment over no adjuvant treatment was found in terms of the duration of the disease-free interval (p < 0.01). No clear advantage of adjuvant treatment was shown with respect to progression to invasive disease, time to appearance of distant metastases or duration of survival and progression-free survival. Median survival followup was 7.8 years. CONCLUSIONS: Despite prologation of the disease-free-interval adjuvant treatment has no apparent long-term impact on the evolution of stage TaTi bladder cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
TNM Classification of Malignant Tumours.
(1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-70-1-248_1 · Cited by 1,094
Effects of Adjuvant Tamoxifen and of Cytotoxic Therapy on Mortality in Early Breast Cancer
Early Breast Cancer Trialists' Collaborative Group (1988) · New England Journal of Medicine · doi:10.1056/nejm198812293192601 · Cited by 933
Lamm, D. L., Blumenstein, B. A., Crawford, E. D., Montie, J. E., Scardino, P., Grossman, H. B., Stanisic, T. H., Smith, J. A., Sullivan, J., Sarosdy, M. F., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110243251703 · Cited by 605
Cancer in the European community and its member states
Møller Jensen, O., Estève, J., Møller, H., & Renard, H. (1990) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(90)90278-2 · Cited by 455
Oosterlinck, W., Kurth, K. H., Schröder, F., Bultinck, J., Hammond, B., Sylvester, R., & Embers of the European Organization for Research and Treatment of Cancer Genitourinary Group (1993) · Journal of Urology · doi:10.1016/s0022-5347(17)36198-0 · Cited by 361
Self-citationHerr, H. W., Schwalb, D. M., Zhang, Z. F., Sogani, P. C., Fair, W. R., Whitmore, W. F., & Oettgen, H. F. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.6.1404 · Cited by 300
Martínez Piñeiro, J. A., León, J. J., Martínez Piñeiro, L., Fiter, L., Mosteiro, J. A., Navarro, J., García Matres, M. J., & Cárcamo, P. (1990) · Journal of Urology · doi:10.1016/s0022-5347(17)40002-4 · Cited by 178
Bouffioux, C., Kurth, K. H., Bono, A., Oosterlinck, W., Kruger, C. B., De Pauw, M., & Sylvester, R. (1995) · Journal of Urology · doi:10.1016/s0022-5347(01)67608-0 · Cited by 174
Self-citationA Low Dose Bacillus Calmette-Guerin Regimen in Superficial Bladder Cancer Therapy: Is it Effective?
Pagano, F., Bassi, P., Milani, C., Meneghini, A., Maruzzi, D., & Garbeglio, A. (1991) · Journal of Urology · doi:10.1016/s0022-5347(17)37707-8 · Cited by 170
MRC WORKING PARTY ON UROLOGICAL CANCER, L. (1985) · British Journal of Urology · doi:10.1111/j.1464-410x.1985.tb07031.x · Cited by 66
Meta-analysis: The fashion of summing-up evidence
Gelber, R. D., & Goldhirsch, A. (1991) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a057993 · Cited by 30
Cited by
Sylvester, R. J., van der Meijden, A. P. M., Oosterlinck, W., Witjes, J. A., Bouffioux, C., Denis, L., Newling, D. W. W., & Kurth, K. (2006) · European Urology · doi:10.1016/j.eururo.2005.12.031 · Cited by 3,013
Self-citationSYLVESTER, R. J., van der MEIJDEN, A. P. M., & LAMM, D. L. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64273-5 · Cited by 1,312
Self-citationEAU Guidelines on Non–Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update
Babjuk, M., Oosterlinck, W., Sylvester, R., Kaasinen, E., Böhle, A., Palou-Redorta, J., & Rouprêt, M. (2011) · European Urology · doi:10.1016/j.eururo.2011.03.017 · Cited by 1,067
Self-citationEAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
Babjuk, M., Oosterlinck, W., Sylvester, R., Kaasinen, E., Böhle, A., & Palou-Redorta, J. (2008) · European Urology · doi:10.1016/j.eururo.2008.04.051 · Cited by 723
Self-citationBrausi, M., Collette, L., Kurth, K., van der Meijden, A. P., Oosterlinck, W., Witjes, J. A., Newling, D., Bouffioux, C., & Sylvester, R. J. (2002) · European Urology · doi:10.1016/s0302-2838(02)00068-4 · Cited by 690
Self-citation
Metadata
- Authors
- Pawinski, A., Sylvester, R., Kurth, K. H., Bouffioux, C., Van Der Meijden, A., Parmar, M. K. B., Bijnens, L., For the Members of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group, & The Medical Research Council Working Party on Superficial Bladder Cancer
- Venue
- Journal of Urology
- Published
- 1996-12
- Volume
- 156
- Issue
- 6
- Pages
- 1934-1941
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W4317523048
- Cited by
- 301
- References
- 13
- FWCI
- 10.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.